These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 15352913)

  • 1. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
    Tsibouris P; Hendrickse MT; Isaacs PE
    Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
    Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
    Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y
    Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
    Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A
    Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.
    Vaughan TL; Dong LM; Blount PL; Ayub K; Odze RD; Sanchez CA; Rabinovitch PS; Reid BJ
    Lancet Oncol; 2005 Dec; 6(12):945-52. PubMed ID: 16321762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's oesophagus: a clinical study of 52 patients.
    Cooper BT; Barbezat GO
    Q J Med; 1987 Feb; 62(238):97-108. PubMed ID: 3498962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
    Tan MC; El-Serag HB; Yu X; Thrift AP
    Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
    Incarbone R; Bonavina L; Bassi F; Peracchia A
    Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
    Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
    Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's oesophagus: the new endoscopic modalities have a future.
    Deviere J
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC; Kania J; Burnat G; Hahn EG
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.